Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s life sciences sector. ...more
11/11/2024
/ Acquisitions ,
AstraZeneca ,
Biotechnology ,
Bristol-Myers Squibb ,
China ,
Johnson & Johnson ,
Life Sciences ,
Medical Devices ,
Mergers ,
Novartis ,
Pharmaceutical Industry ,
Popular
This is the first of two articles focused on 2023 life sciences deals in China. The second article, which is coming soon, looks at trends in M&A.
In 2023, there were 240 reported life sciences licensing deals in China,...more
On May 26, 2023, the European Commission granted the marketing authorization to Samsung Bioepis for EPYSQLI, a biosimilar referencing SOLIRIS (eculizumab) developed by Alexion for the treatment of the paroxysmal...more